SEC Filing Summary: Imprimis Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on July 23, 2013. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The registrant is incorporated in Delaware with principal executive offices in San Diego, CA.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation rather than a financial statement.
Material Changes
No material financial changes versus a prior period are reported in this document. The filing discloses the use of a management presentation (Exhibit 99.1) in meetings describing the Company.
Guidance, Outlook, and Risks
The filing references a presentation dated July 2013 attached as Exhibit 99.1. The text explicitly states that the information contained in Item 7.01 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference, except as expressly set forth by specific reference. No specific guidance, risks, or contingencies are detailed within the body of this 8-K.
Key Facts for Investor Verification
- Verify the contents of Exhibit 99.1 (Presentation dated July 2013) for actual business updates, as the 8-K only references its existence.
- Confirm that the presentation is not legally "filed" or incorporated by reference unless specifically cited in other filings.
- Note the discrepancy between the request metadata ("HARROW, INC.") and the actual registrant name in the filing text ("Imprimis Pharmaceuticals, Inc.").